Samsung Biologics, Amgen and Biocon invest in US pharma sites

Group 1: Industry Trends - International drugmakers are increasing investments in the U.S. to be closer to key markets amid tariff pressures affecting global trade and supply chains [1][2] - Although pharmaceutical imports are exempt from U.S. tariffs, there are ongoing threats from the Trump administration to raise tariffs significantly, potentially up to 250% [2] Group 2: Company Investments - Samsung Biologics has signed a nearly $1.3 billion contract manufacturing deal with an undisclosed U.S. pharmaceutical company, which is set to run through December 2029 [3] - Prior to the recent deal, Samsung Biologics secured a $514 million contract with another U.S. drugmaker and a $1.2 billion contract with an Asia-based pharmaceutical company [4] - Amgen plans to invest over $600 million to establish a science and innovation center at its headquarters in Thousand Oaks, California, aimed at accelerating R&D for next-generation medicines [5] - Amgen's recent investments also include a $900 million factory expansion in Central Ohio and a $1 billion manufacturing plant in Holly Springs, North Carolina, with over $40 billion invested in manufacturing and R&D since 2017 [6]